Is Honey Good for Fatty Liver Disease?

Is honey good for fatty liver disease? It is a question many people ask when looking for natural ways to support liver health, but the answer is more nuanced than popular wellness advice suggests. While honey contains antioxidant compounds that have shown some promise in laboratory research, no UK clinical guideline recommends it as a therapeutic food for fatty liver disease. In fact, because honey is classified as a free sugar under NHS and SACN guidance, consuming it in excess may worsen the very metabolic processes that drive fat accumulation in the liver. This article explains what the evidence actually shows.

Is honey good for fatty liver disease?

Honey is not a recommended treatment for fatty liver disease under UK clinical guidelines, and its high free-sugar content means it should be used sparingly rather than viewed as a liver health food.

Honey is not a recommended treatment for fatty liver disease, and no UK clinical guideline endorses it as a therapeutic food for this condition. The British Liver Trust and NICE (NG49) do not include honey in their dietary guidance for fatty liver disease, and the NHS does not list it as a beneficial food for liver health.^[1]

Fatty liver disease sits within the broader category of steatotic liver disease (SLD). The two main subtypes are metabolic dysfunction-associated steatotic liver disease (MASLD), which is driven by metabolic risk factors such as obesity, type 2 diabetes and dyslipidaemia, and alcohol-related liver disease (ALD), which is caused by harmful alcohol use. A third category, MetALD, describes people who have both significant metabolic risk factors and harmful alcohol intake. These are distinct conditions, though they share the feature of excess fat accumulating within liver cells. Management of all forms is centred on sustained lifestyle change rather than individual foods or supplements.

Honey is not necessarily harmful in small amounts for most people with fatty liver, and some laboratory research has explored whether certain compounds in honey, particularly polyphenols and antioxidants, might have a protective effect on liver tissue. However, this research is largely preclinical (conducted in cell cultures or animal models) and cannot yet be translated into dietary recommendations for people.

It is also worth noting that honey is a concentrated source of simple sugars, primarily fructose and glucose. Under UK guidance from the Scientific Advisory Committee on Nutrition (SACN) and the NHS, honey counts as a free sugar, and adults are advised to consume no more than 30 grams of free sugars per day.^[2][3] Excess fructose intake is of particular concern in fatty liver disease because the liver metabolises fructose directly, and high consumption has been associated with increased fat deposition in liver cells. For this reason, honey should be used sparingly, in the same way as other added sugars, rather than viewed as a health food for liver conditions.

If you have been diagnosed with fatty liver disease and are considering dietary changes, speaking with your GP or a registered dietitian is the most appropriate first step. They can provide personalised guidance based on your overall health, weight and any other conditions you may have.

What does the evidence say about honey and liver health?

Current evidence is preliminary and largely preclinical; no high-quality randomised controlled trial has shown that honey improves liver fat, enzyme levels or clinical outcomes in fatty liver disease.

The current evidence on honey and liver health is preliminary and does not support specific clinical recommendations. Most studies have been conducted in animal models or small laboratory settings, and results have not been consistently replicated in well-designed human clinical trials. Some research has suggested that the antioxidant compounds found in honey, including flavonoids and phenolic acids, may reduce markers of oxidative stress in liver tissue in preclinical models, but these findings have not been confirmed in large-scale human studies relevant to fatty liver disease.

A small number of human studies have examined honey's effect on metabolic markers such as blood glucose, cholesterol and liver enzymes. Results have been mixed, and the quality of evidence is generally low, with limitations including small sample sizes, short durations and lack of standardisation in the type of honey used. Different varieties of honey vary considerably in their polyphenol content, making it difficult to draw generalisable conclusions. Systematic reviews of honey and cardiometabolic outcomes have not identified consistent, clinically meaningful benefits.^[14]

Importantly, no randomised controlled trial of sufficient quality has demonstrated that honey consumption improves liver fat content, liver enzyme levels or clinical outcomes in people with MASLD or alcohol-related liver disease. The British Liver Trust and NICE NG49 do not include honey in their dietary guidance for fatty liver disease.^[1]

In summary, while the biological plausibility of some benefit exists based on preclinical data, the evidence base is too limited and inconsistent to recommend honey as part of a liver-health strategy. Patients should be cautious about interpreting early-stage research as clinical guidance, and should prioritise evidence-based dietary patterns over individual foods.

How much sugar does honey contain, and does that matter?

Honey is approximately 80% sugar by weight, with fructose making up around 38 to 40%; this matters because excess fructose is processed in the liver and can promote fat accumulation in MASLD.

Honey contains approximately 80% sugar by weight, composed mainly of fructose (around 38 to 40%) and glucose (around 30 to 35%), with small amounts of other sugars and water making up the remainder, according to UK food composition data (McCance and Widdowson's The Composition of Foods).^[5] This high sugar content is directly relevant to fatty liver disease, because the liver plays a central role in processing dietary fructose.

Unlike glucose, which is metabolised throughout the body, fructose is processed almost exclusively in the liver. When consumed in large quantities, fructose can promote de novo lipogenesis, the process by which the liver converts excess sugar into fat. This is one of the mechanisms thought to contribute to the development and progression of MASLD. For this reason, dietary guidance for people with fatty liver disease consistently emphasises reducing intake of added sugars, including those found in honey, fruit juices, fizzy drinks and confectionery.

The NHS recommends that adults consume no more than 30 grams of free sugars per day, based on SACN guidance. Under this definition, honey counts as a free sugar. A single teaspoon of honey (approximately 7 grams) contains around 5 to 6 grams of free sugars, so even modest use can contribute meaningfully to daily intake.^[5][2] Replacing refined sugar with honey does not meaningfully reduce the metabolic burden on the liver, as both deliver similar quantities of fructose and glucose.

For people managing fatty liver disease, the overall pattern of sugar intake matters more than the source. Honey is not a safer alternative to table sugar in this context, and treating it as a health food could inadvertently increase total sugar consumption. Moderation and awareness of portion size are key.

Which foods and drinks are recommended for a fatty liver?

A Mediterranean-style diet rich in vegetables, wholegrains, oily fish and olive oil has the strongest evidence base for improving liver health in MASLD, as supported by NICE NG49 and the British Liver Trust.

A diet rich in vegetables, wholegrains, lean protein and healthy fats is broadly recommended for people with fatty liver disease, and this pattern aligns closely with a Mediterranean-style diet, which has the strongest evidence base for improving liver health in MASLD.^[1][16] The British Liver Trust and NICE NG49 both highlight the importance of overall dietary quality rather than focusing on individual superfoods.

Foods and drinks that are generally considered beneficial or neutral for liver health include:

• Vegetables and legumes: Broccoli, spinach, lentils and beans provide fibre and antioxidants without adding significant sugar load.

• Wholegrains: Oats, brown rice and wholemeal bread support stable blood glucose levels and reduce the glycaemic burden on the liver.

• Oily fish: Salmon, mackerel and sardines provide omega-3 fatty acids, which have been associated with reduced liver fat in some studies, though evidence in people with MASLD remains preliminary.^[15][16]

• Olive oil: Used in place of saturated fats, extra virgin olive oil is a key component of the Mediterranean diet and has anti-inflammatory properties.

• Coffee: Observational studies have consistently associated regular coffee consumption with lower rates of liver fibrosis and cirrhosis, and the British Liver Trust acknowledges this evidence, though the mechanism is not fully understood and coffee cannot be considered a treatment.^[11][12]

• Water: Staying well hydrated supports overall metabolic function. Sugary drinks, including fruit juices and fizzy drinks, should be minimised.

Foods to limit include red and processed meat, refined carbohydrates, ultra-processed foods, alcohol and, as discussed, added sugars including honey in large quantities. A registered dietitian can help tailor these principles to individual needs. Bolt Pharmacy is a GPhC-registered online pharmacy in Great Britain offering online weight-management consultations, with prescriber review and pharmacist support; weight management services may be relevant for those whose fatty liver is linked to excess weight, and any prescription medicine would only be provided where clinically appropriate following a consultation.

What lifestyle changes does the NHS recommend for fatty liver?

The NHS recommends gradual weight loss of 5 to 10% of body weight, at least 150 minutes of moderate aerobic activity per week, and a diet low in added sugars and saturated fat as the cornerstone of MASLD management.

The NHS recommends that the most effective approach to managing MASLD is a combination of gradual weight loss, regular physical activity and a balanced diet low in added sugars and saturated fat. There is currently no medicine licensed specifically for MASLD in the UK, though this should be verified against current MHRA and NICE guidance at the time of reading, as the licensing landscape may change. Lifestyle modification therefore remains the cornerstone of management.

Key NHS-aligned recommendations include:

• Weight loss: Losing 5 to 10% of body weight has been shown to reduce liver fat and improve liver enzyme levels, as set out in NICE NG49.^[1] More substantial weight loss (greater than 10%) may lead to improvement in liver inflammation and fibrosis in some people.^[1][18] Weight loss should be gradual and sustained; very rapid weight loss is not recommended as it may not be beneficial and is difficult to maintain.

• Physical activity: The UK Chief Medical Officers' guidelines recommend at least 150 minutes of moderate-intensity aerobic activity per week, such as brisk walking, cycling or swimming.^[7][8] Resistance exercise also has benefits for metabolic health and liver fat reduction.

• Alcohol: People with MASLD are advised to stay within the UK Chief Medical Officers' low-risk drinking guidelines of no more than 14 units of alcohol per week, spread across several days.^[6] Those with alcohol-related liver disease should abstain entirely.

• Avoiding unnecessary supplements: Some herbal supplements and high-dose vitamins can be harmful to the liver. Always inform your GP before taking any supplement. If you experience a suspected adverse reaction to a medicine, vaccine, herbal or vitamin product, you can report it via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk.

• Regular monitoring: People with fatty liver disease should have regular follow-up with their GP to monitor liver function tests, weight and any associated conditions such as type 2 diabetes or high cholesterol. NICE NG49 recommends that GPs use non-invasive scoring tools such as the FIB-4 or NAFLD Fibrosis Score to assess the risk of advanced fibrosis, with onward referral for specialist assessment (which may include elastography or the Enhanced Liver Fibrosis test) where scores indicate higher risk.

If you are concerned about your liver health, contact your GP in the first instance. Jaundice (yellowing of the skin or eyes) should prompt a same-day GP appointment or contact with NHS 111. If jaundice occurs alongside red-flag features such as severe abdominal pain, confusion, high fever or signs of bleeding, seek emergency care via 999 or your nearest A&E department.

Scientific References

1. Metabolic dysfunction-associated steatotic liver disease (MASLD): assessment and management (NG49).
2. Sugar: the facts.
3. SACN Carbohydrates and Health Report.
4. SACN Report: Drastic Action on Sugar Consumption Recommended.
5. Composition of foods integrated dataset (CoFID) — McCance and Widdowson's The Composition of Foods.
6. Alcohol consumption: advice on low risk drinking.
7. Physical activity guidelines: UK Chief Medical Officers' report.
8. Physical activity guidelines for adults aged 19 to 64.
9. Non-alcoholic fatty liver disease (NAFLD).
10. Resmetirom (Rezdiffra) authorised to treat metabolic dysfunction-associated steatohepatitis (MASH) in adults.
11. Coffee consumption and risk of nonalcoholic fatty liver disease: a systematic review and meta-analysis.
12. The effect of coffee consumption on non-alcoholic fatty liver disease and liver fibrosis: a meta-analysis of 11 epidemiological studies.
13. Effect of Coffee Consumption on Non-Alcoholic Fatty Liver Disease Incidence, Prevalence and Risk of Significant Liver Fibrosis: Systematic Review with Meta-Analysis of Observational Studies.
14. Dosage exploration of the effects of honey and its derivatives on cardiometabolic outcomes: an overview of systematic reviews and GRADE-assessed meta-analyses.
15. Influence of Lipid Class Used for Omega-3 Fatty Acid Supplementation on MASLD.
16. The impact of dietary interventions on liver health biomarkers in individuals with MASLD: a systematic literature review and meta-analysis of randomized controlled trials.
17. Omega-3 polyunsaturated fatty acids and nonalcoholic fatty liver disease in adults: a meta-analysis of randomized controlled trials.
18. Weight Loss as a Determinant of Histological Improvement in MASLD in People With Obesity: A Systematic Review and Network Meta-Analysis of Randomised Clinical Trials.
19. The Impact of Body Weight Change on Liver Histology in MASLD Across Various Histological Endpoints: A Systematic Review and Meta-Analysis.
20. The physiology of MASLD: molecular pathways between liver and adipose tissues.

Frequently Asked Questions